Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.

Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC

The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC 

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.

Prophylactic Tocilizumab Reduces Toxicity, Boosts Efficacy in Immune Checkpoint Inhibitor–Treated Melanoma

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

R. Lor Randall, MD, FACS, discusses the construction and preclinical utility of spheroid models for drug development in osteosarcoma. 

Osteosarcoma Spheroid Models Provide Key Tool for Preclinical Drug Development 

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Jonathan Wesley Riess, MD, MS, details the potential for ivonescimab in NSCLC after improving PFS vs pembrolizumab in the HARMONi-2 trial.

The Novel Bispecific Antibody Ivonescimab May be Poised to Change the SOC in NSCLC

Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.

Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC 

The podcast section includes OncLive on Air® podcast episodes, which focus on clinical oncology news and expert insights in cancer care. Listen on OncLive.

Podcasts | Clinical Oncology News & Insights | OncLive

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, supported by Sanofi, we had the pleasure of speaking with Philippe Moreau, MD, about updates from the phase 3 IMROZ trial (NCT03319667) of isatuximab-irfc (Sarclisa), bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (Isa-VRd) in patients with newly diagnosed multiple myeloma. Dr Moreau is head of the Hematology Department at the University Hospital of Nantes, as well as a university professor of Clinical Hematology at Nantes Faculty of Medicine in France.

In our exclusive interview, Dr Moreau discussed key findings from an analysis of minimal residual disease negativity dynamics from IMROZ and the potential future implications of these findings for patients with newly diagnosed multiple myeloma who receive treatment with Isa-VRd.

That’s all we have for today! Thank you for listening to this episode of 

, supported by Sanofi. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

 is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Dr Moreau highlights key findings on MRD negativity dynamics from IMROZ and their future implications for patients with newly diagnosed multiple myeloma.

Explore MRD Dynamics With Isa-VRd in Newly Diagnosed Multiple Myeloma: Insights From Philippe Moreau, MD

Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing

In today’s episode, supported by BeiGene, we had the pleasure of speaking with Mazyar Shadman, MD, MPH, about updates in zanubrutinib (Brukinsa)–focused research in chronic lymphocytic leukemia (CLL) that were presented at the 2024 ASH Annual Meeting. Dr Shadman is an associate professor in the Clinical Research Division and the medical director of Cellular Immunotherapy at the Fred Hutchinson Cancer Center in Seattle, Washington.

In our exclusive interview, Dr Shadman discussed key findings and implications from several clinical trials investigating zanubrutinib as monotherapy and in combination with agents such as obinutuzumab (Gazyva), sonrotoclax (BGB-11417), and venetoclax (Venclexta) in patients with CLL and other B-cell malignancies.

, supported by BeiGene. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

 is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Dr Shadman discusses key findings and implications from trials that were presented at the 2024 ASH Annual Meeting investigating zanubrutinib in CLL.

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life’s experiences.

In this episode, Dr Camidge sits down with Mary Redman, PhD, a biostatistician and professor of clinical research at Fred Hutchinson Cancer Center in Seattle, Washington.

Drs Camidge and Redman discuss Dr Redman's role as a biostatistician, outlining her work in designing clinical trials, navigating collaborations with multidisciplinary care teams, and the challenges of coordinating efforts across a nationwide network of clinical researchers.

Drs Camidge and Redman discuss Dr Redman's role as a biostatistician at Fred Hutch, outlining her work in designing clinical trials. 

Designing Trials and Fueling Collaboration in Oncology: With D. Ross Camidge, MD, PhD; and Mary Redman, PhD

In today’s episode, we had the pleasure of speaking with Andre Goy, MD, about key updates from the 2024 ASH Annual Meeting. Dr Goy is physician in chief of Hackensack Meridian Health Oncology Care Transformation Services, as well as the chairman, chief physician officer, and chief of the Lymphoma Division at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey.

In our exclusive interview, Dr Goy discussed top hematologic oncology research conducted by his colleagues at the John Theurer Cancer Center and his predictions for the future of the field in 2025 and beyond.

. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

Andre Goy, MD, discusses top hematologic oncology research from the 2024 ASH Annual Meeting.

Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD

®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

In today’s episode, we had the pleasure of speaking with Sagar D. Sardesai, MBBS, about the phase 3 ELAINE-3 trial (NCT05696626) and its evaluation of lasofoxifene in combination with abemaciclib (Verzenio) for patients with 

-mutant, estrogen receptor (ER)–positive, HER2-negative locally advanced or metastatic breast cancer. Dr Sardesai is a breast medical oncologist and researcher in the Division of Medical Oncology at The Ohio State University (OSU) and a member of the Cancer Control Program at OSU Comprehensive Cancer Center – James in Columbus.

The trial aims to compare progression-free survival (PFS) outcomes for lasofoxifene plus abemaciclib vs fluvestrant (Faslodex) plus abemaciclib in patients who have previously received a frontline aromatase inhibitor in combination with a CDK4/6 inhibitor other than abemaciclib.

In our exclusive interview, Dr Sardesai provided insights into ELAINE-3's objectives, the challenges of patient enrollment, and the potential implications for lasofoxifene in clinical practice. He emphasized the importance of personalized treatment approaches, especially in patients harboring 

 mutations, and how the combination therapy with lasofoxifene and abemaciclib could potentially address the unmet need for effective, targeted therapies.

 On Air. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit 

OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

Sagar D. Sardesai, MBBS, discusses the phase 3 ELAINE-3 trial evaluating lasofoxifene plus abemaciclib in ESR1-mutant, ER+/HER2- metastatic breast cancer.

Exploring Lasofoxifene Plus Abemaciclib in ESR1+ Breast Cancer: Insights from ELAINE-3 With Sagar D. Sardesai, MBBS

! I’m your host today, Courtney Flaherty.

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Alex F. Herrera, MD, about key safety and efficacy findings from the 

 evaluating nivolumab (Opdivo) plus doxorubicin, vinblastine, and dacarbazine (N+AVD) vs brentuximab vedotin (BV) plus AVD (BV+AVD) in adolescent and adult patients with stage III or IV advanced-stage classic Hodgkin lymphoma. Herrera is chief of the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation, as well as the associate medical director of the Briskin Center for Clinical Research and an associate professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California.

After 2.1 years of follow-up (range, 0-4.2), N+AVD prolonged median progression-free survival (PFS) and had a more tolerable safety profile compared with BV+AVD. The 2-year PFS rate with N+AVD was 92% (95% CI, 89%-94%) vs 83% (95% CI, 79%-86%) with BV+AVD (HR, 0.45; 95% CI, 0.30-0.65). Notably, the benefit with N+AVD was consistent across diverse patient subgroups enrolled in the study.

In our exclusive interview, Dr Herrera expanded on the rationale for conducting SWOG S1826, detailed key data showing sustained benefit and safety with N+AVD, and explained how these results support the use of N+AVD as a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin lymphoma.

That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Dr Herrera explains why N+AVD is a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin lymphoma.

Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD

, host Chandler Park, MD, a medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, was rejoined by Stephen Liu, MD, a thoracic oncologist and the Head of Developmental Therapeutics at Georgetown University’s Lombardi Comprehensive Cancer Center in Washington, DC. 

Their conversation encompassed findings from the phase 3 MARIPOSA trial (NCT04487080) investigating amivantamab-vmjw (Rybrevant) plus lazertinib (lacluze) in patients with 

-mutated advanced non–small cell lung cancer (NSCLC); toxicities associated with amivantamab and lazertinib to be aware of; the potential future implications of findings from the phase 3 PALOMA-3 trial (NCT05388669) of lazertinib plus subcutaneous amivantamab in patients with 

-mutated advanced or metastatic NSCLC; and how all these agents may fit into the NSCLC treatment armamentarium going forward.

Drs Park and Liu discuss the use of amivantamab plus lazertinib in EGFR-mutated non–small cell lung cancer. 

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD  

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, supported by Daiichi Sankyo, we had the pleasure of speaking with Misako Nagasaka, MD, PhD, about the use of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in patients with non–small cell lung cancer (NSCLC). Dr Nagasaka is an associate professor in the Division of Hematology and Oncology and the Division of Medicine at the University of California Irvine School of Medicine. 

In our exclusive interview, Dr Nagasaka discussed key findings from the phase 2 DESTINY-PanTumor02 (NCT04482309) and DESTINY-Lung01 (NCT03505710) trials that led to the FDA approval of T-DXd for patients with unresectable or metastatic HER2-positive solid tumors, including those with NSCLC; where next-generation sequencing fits into her clinical practice; and the current role of T-DXd in lung cancer management.

That’s all we have for today! Thank you for listening to this episode of 

supported by Daiichi Sankyo. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

 is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

Dr Nagasaka discusses the use of T-DXd in patients with unresectable or metastatic HER2-positive NSCLC.

T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD

Thanks for your interest in this podcast. Please read this important program information before listening.

This featured podcast includes a discussion with 2 experts on management of adverse events associated with treatment options for diffuse large B-cell lymphoma (DLBCL) along the therapeutic continuum. In particular, the faculty members discuss how novel immunotherapy options fit within the standard of care along the therapeutic continuum. This activity is supported by an educational grant from Pfizer Inc.

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 

 Physicians should claim only the credit commensurate with the extent of their participation in the activity.

You may immediately download your certificate.

Associate Professor
Medical Director, Cellular Therapy
Associate Vice-Chair Research, Department of Medicine
Assistant Vice Chancellor for Clinical Research
Fred & Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, NE

Professor-Clinical, Division of Hematology
Director, Lymphoma Program
Associate Division Director for Ambulatory Operations, Division of Hematology
Medical Director, Infusion Services
Associate Chief Medical Officer, The James Cancer Hospital
Chief of Staff - Elect, The James Cancer Hospital
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Colombus, OH

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Burst CME™: Tackling Adverse Events with Targeted Therapies for Diffuse B-cell Lymphoma

that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays. 

Podcasts

All Podcast Series

How This Is Building Me

Two Onc Docs

Blood Club

FDA Approval Insights

Oncology Expert Insights

OncClub

Conference Perspectives

Women In Oncology

Rare Cancers

Disparities

Fellowship

Roundtable Discussions

CME Podcasts

Latest Conference Coverage